General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Annual results

Annual Results 2011 - Jan 25, 2012

2011
(USD m)
2010
(USD m)
% change
(USD)
Net sales 58,566 50,624 16
Operating income 10,998 11,526 -5
Net income 9,245 9,969 -7
Basic EPS (USD) USD 3.83 USD 4.28 -11
Core
Operating income 15,909 14,006 14
Net income 13,490 12,029 12
Basic EPS (USD) USD 5.57 USD 5.15 8

Media release

The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Stock chart